Benefits of ultraIPV™

The method allows the production of more doses per unit of purified viruses. The use of attenuated strains reduces biohazard and biosafety concerns surrounding the current production of inactivated polio vaccine (IPV) from pathogenic strains.

Polio Types 2 and 3 have already been eradicated and efforts continue to eradicate Polio 1. Once eradicated, the WHO advises that countries continue to maintain vaccine vigilance for 20-30 years. After eradication, the biosafety concerns associated with manufacturing IPV from pathogenic strains will become increasingly serious.

ultraIPV™ Provides:

Improved immunogenicity
Greater Efficacy
Cost & time benefits and comparison against current/competing processes
Reduced manufacturing costs
Reduced Biosecurity threat
Safer for recipients and populations